Takeda’s FY2021 Sales Up 11.6%; Weak Yen Tailwind for Revenue, but Drags Profits

Takeda Pharmaceutical closed its books with 11.6% growth in FY2021, pushed up by foreign exchange fluctuations and strong underlying performances. A gain from its diabetes portfolio sale to Teijin Pharma and a contribution from Moderna’s COVID-19 jab helped it offset...read more